关注公众号

关注公众号

手机扫码查看

手机查看

喜欢作者

打赏方式

微信支付微信支付
支付宝支付支付宝支付
×

Keynote Speaker: Liuming Yu

2019.7.16

Liuming Yu

  Mr. Yu, Chairman & CEO of Suzhou Evermed Biomedical Co., Ltd (“Evermed”), is a well-known expert in development of liquid reagents for measurement of small molecules using Homogeneous Enzyme Immunoassay (HEIA) methodology. Prior to his tenure at Evermed he held a prestigious position as the R&D Director at Quest Diagnostic, the largest reference laboratory in the world. He also served as the inspector and the Chinese ambassador of CAP (College of American Pathologists). Since founding Suzhou Evermed in 2012 he headed his company to develop more than 100 HEIA assays, acquired more than 30 China invention patents, and successfully received cFDA approvals for twelve clinical HEIA products. His achievements were recognized and won multiple local and national awards including: “National Torch Plan”, “Jiangsu Science and Technology Achievement”, “Jiangsu Double-Creation Reward”, and “Suzhou Leadership Award”. In 2013 Evermed was the first IVD company in China to utilize the HEIA methodology for clinical diagnostic testing. Within a few years, HEIA products have been widely accepted by many clinical laboratories in China. Tested analytes include a broad range of clinical markers covering: Therapeutic Drug Monitoring (TDM), Endocrines, Metabolites, Drugs of Abuse (DOA), and Adulterants.

中国分析测试协会
文章提到的专题
推荐
热点排行
一周推荐
关闭